How much revenue does Taho Pharma make?

Taho Pharma reported 8.41 million TWD in revenue for fiscal year 2025. In Q2 2026 revenue was 1.34 million TWD.

What companies are similar to Taho Pharma?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Gongwin Biopharm Holdings Co., Ltd. (6617.TWO), Foresee Pharmaceuticals Co., Ltd. (6576.TWO), PharmaEngine, Inc. (4162.TWO), Acepodia, Inc. (6976.TWO).

Taho Pharma (6467.TWO) Stock

About Taho Pharma

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; ...

At a glance

Taho Pharma reported revenue of 8.41 million TWD for fiscal year 2025, and net income of -214.40 million TWD. In Q2 2026 (the quarter ended June 30, 2026) revenue was 1.34 million TWD.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.